Status:

RECRUITING

Tfh Dysfunction in HIV and Aging

Lead Sponsor:

University of Miami

Conditions:

Human Influenza

Eligibility:

All Genders

18+ years

Phase:

PHASE4

Brief Summary

The purpose of this research is to evaluate blood samples from HIV infected and non-HIV infected people to understand how aging and HIV infection affect the immune responses (body defenses against inf...

Eligibility Criteria

Inclusion

  • Inclusion Criteria:
  • For HIV positive participants:
  • HIV infection, as documented by any licensed ELISA test kit. Participants on ART as a result of prior HIV documented infection will not be required to provide proof of diagnosis of HIV infection.
  • Additional criteria for HIV positive
  • on ART for at least 1 year. Occasional viral blips up to 1000 copies/ml also acceptable provided the patients are on continuing treatment,
  • Cluster of differentiation 4 (CD4) count available in the prior 6 months and \>200/mm3
  • Undetectable viral load (\< 40 copies/mL). Blips of \<1000 copies/mL will be allowed.
  • For HIV negative participants:
  • Documented negative HIV test at the time of study entry, either by any licensed ELISA.
  • For all participants:
  • Individuals age: ≤35 years and ≥65 years.
  • No history of other immunodeficiency disorders
  • Not on steroid or other immunosuppressive/immunomodulators medications.
  • No active malignancies.
  • Agreeable to receive both regular standard (STD-TIV) and high dose (HD-TIV) influenza vaccination.
  • Agreeable to participate in study for a complete course of study full visits including 2 consecutive flu seasons.
  • Able to provide informed consent.
  • Exclusion criteria
  • Contraindication to receive influenza vaccination.
  • Non-adherence to ART for HIV positive
  • Unable to provide informed consent.
  • Influenza vaccination already given during the current vaccination season.
  • Known drug abuse including cocaine by history

Exclusion

    Key Trial Info

    Start Date :

    October 30 2020

    Trial Type :

    INTERVENTIONAL

    Allocation :

    ESTIMATED

    End Date :

    December 30 2026

    Estimated Enrollment :

    400 Patients enrolled

    Trial Details

    Trial ID

    NCT04487041

    Start Date

    October 30 2020

    End Date

    December 30 2026

    Last Update

    May 30 2025

    Active Locations (1)

    Enter a location and click search to find clinical trials sorted by distance.

    Page 1 of 1 (1 locations)

    1

    University of Miami

    Miami, Florida, United States, 33136